Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.